SCHEMBL1606536

SCHEMBL1606536

CCC1(C(C)C)SC(N[C@H]2C[C@H]3CC[C@H]2C3)=NC1=O

nearest known ligand 0.33

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 5/20 0.33
BRS3 P32247 4/20 0.33
PDGFRB P09619 3/20 0.32
PDGFRA P16234 3/20 0.32
PANK3 Q9H999 1/20 0.32
P2RX7 Q99572 1/20 0.31
JAK2 O60674 1/20 0.31
JAK1 P23458 1/20 0.31
TAS1R3 Q7RTX0 1/20 0.31
TAS1R1 Q7RTX1 1/20 0.31
TAS1R2 Q8TE23 1/20 0.31
CNR2 P34972 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10285069 1.00 HSD11B1 (0.33) HSD11B1BRS3PDGFRBPDGFRAPANK3
SCHEMBL10284825 1.00 HSD11B1 (0.33) HSD11B1BRS3PDGFRBPDGFRAPANK3
SCHEMBL1606533 1.00 HSD11B1 (0.33) HSD11B1BRS3PDGFRBPDGFRAPANK3
SCHEMBL12738012 1.00 HSD11B1 (0.33) HSD11B1BRS3PDGFRBPDGFRAPANK3
SCHEMBL14344801 0.83 TAS1R3 (0.33) BRS3PDGFRBPDGFRAPANK3P2RX7
SCHEMBL1606100 0.83 TAS1R3 (0.33) BRS3PDGFRBPDGFRAPANK3P2RX7
SCHEMBL1606099 0.83 TAS1R3 (0.33) BRS3PDGFRBPDGFRAPANK3P2RX7
SCHEMBL1605633 0.83 TAS1R3 (0.33) BRS3PDGFRBPDGFRAPANK3P2RX7
SCHEMBL1606036 0.81 HSD11B1 (0.36) HSD11B1BRS3PDGFRBPDGFRAPANK3
SCHEMBL13105880 0.81 HSD11B1 (0.43) HSD11B1BRS3PDGFRBPDGFRAP2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8541592-B2 Inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 AMGEN INC. (US) 2013-09-24 US disclosed
US-20120010256-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB 2012-01-12 US disclosed
US-20110082107-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 AMGEN INC. 2011-04-07 US disclosed
EP-1753736-B1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 AMGEN INC (US) 2008-12-17 EP disclosed
US-20070281938-A1 Inhibitors of 11-Beta-Hydroxy Steroid Dehydrogenase Type 1 AMGEN INC. 2007-12-06 US disclosed
US-20070197598-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 AMGEN INC. 2007-08-23 US disclosed
US-7253196-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 AMGEN, INC. (US) 2007-08-07 US disclosed
US-20060142357-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 AMGEN INC. 2006-06-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110082107-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD3B1, HSD17B1 HSD11B1 1/4885BRS3 2744/4885PDGFRB 4134/4885
US-20070197598-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD11B2 HSD11B1 1/4885BRS3 3971/4885PDGFRB 4042/4885
US-20060142357-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD3B1, HSD17B1 HSD11B1 1/4885BRS3 2744/4885PDGFRB 4134/4885
US-20120010256-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD3B1, HSD17B1 HSD11B1 1/4885BRS3 2744/4885PDGFRB 4134/4885
US-20070281938-A1 Inhibitors of 11-Beta-Hydroxy Steroid Dehydrogenase Type 1 HSD11B1, HSD3B1, HSD17B1 HSD11B1 1/4885BRS3 2763/4885PDGFRB 3365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.